B
Bull
Bull · 25%PHGE
$0.42
Szenariopreis
$0.138
+0.006 (+4.69%)Zum Schluss
Loading chart…
- High
- 0.150
- Open
- 0.134
- VWAP
- 0.14
- Vol
- 3.48M
- Mkt Cap
- 23.61M
- Low
- 0.130
- Amount
- 484.75K
- EV/EBITDA, TTM
- 0.00
BiomX Inc. is a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The Company offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus.
AI analysis of BiomX Inc (PHGE)
sellBiomx Inc is not a good buy right now due to significant financial instability and negative market sentiment. The stock has a current price of 0.14, with a year-to-date change of -93.53%, indicating severe underperformance. Additionally, the company has reported a net income loss of -19,225,000 in Q1 2026, raising concerns about its financial viability.
Bewertungskennzahlen
The current forward P/E ratio for BiomX Inc (PHGE) is 0.00, compared to its 5-year average forward P/E of -0.92.
Alphio AI Price Scenarios for PHGE
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
7.508-14NewsfilterBiomX Subsidiary Secures $300,000 Defense Order
8.508-05seekingalphaBiomX Acquires 10% Stake in Motomea to Enhance Drone Testing Capabilities
8.507-28GlobenewswireBiomX Amends Terms of Zorronet Acquisition
- 8.507-28Newsfilter
BiomX Amends Terms for Zorronet Acquisition
7.507-27NASDAQ.COMBiomX Subsidiary Zorronet Expands European Market Presence
PHGE FAQ — answered by Alphio AI
BiomX Inc. is a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The Company offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Biomx Inc is not a good buy right now due to significant financial instability and negative market sentiment. The stock has a current price of 0.14, with a year-to-date change of -93.53%, indicating severe underperformance. Additionally, the company has reported a net income loss of -19,225,000 in Q1 2026, raising concerns about its financial viability.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.